Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WG201
- Development stage
- Preclinical
- Lead developer
- Wingor Biotechnology
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
WG201 is a preclinical-stage extracellular vesicle-conjugated small nucleic acid drug being developed by Wingor Biotechnology. It is developed using Wingor's winEx™ extracellular vesicle technology platform, which focuses on utilizing engineered extracellular vesicles (exosomes) to deliver nucleic acid therapeutics (such as siRNA or mRNA) to target cells. The platform aims to overcome delivery efficiency barriers and facilitate the clinical translation of extracellular vesicle-conjugated drugs.
- Other names
- Extracellular Vesicle Drug Pipeline细胞外囊泡偶联小核酸药物细胞外囊泡药物管线
Beyond the preview
Go deeper on WG201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WG201.